SCHEMBL904084

SCHEMBL904084

OCC1C2CNCC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2281952 1.00
SCHEMBL2378612 1.00
SCHEMBL8227572 1.00
SCHEMBL903981 1.00
SCHEMBL10067708 1.00
SCHEMBL24267539 1.00
SCHEMBL5325155 1.00
Hydrochloric Acid SCHEMBL14779398 0.97
Hydrochloric Acid SCHEMBL21712963 0.97
Hydrochloric Acid SCHEMBL14779396 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888525-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-02-20 EP claimed
WO-2006117754-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO claimed
EP-4748840-A1 IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF TAINUORUI (TIANJIN) BIOTECHNOLOGY CO., LTD (CN) 2026-05-27 EP disclosed
WO-2025039774-A1 IMIDAZO[1,2-A]PYRIDINE TYPE IRAK DEGRADATION AGENT AND USE THEREOF 泰诺瑞(天津)生物科技有限责任公司 2025-02-27 WO disclosed
CN-119019370-A Degradation agent targeting SIRT6 and/or GSPT1 and application thereof 深圳大学 2024-11-26 CN disclosed
CN-118955497-A Imidazo [1,2-a ] pyridine IRAK4 degradation agent and application thereof 泰诺瑞(天津)生物科技有限责任公司 2024-11-15 CN disclosed
WO-2024153173-A1 AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 浙江海正药业股份有限公司 2024-07-25 WO disclosed
CN-117580575-A Glutarimide substituted isoxazole fused ring compound and application thereof 南京明德新药研发有限公司 2024-02-20 CN disclosed
EP-3654968-B1 METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-16 EP disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
WO-2023023255-A1 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF NURIX THERAPEUTICS, INC. (US) 2023-02-23 WO disclosed
EP-1326619-A2 PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY Merck & Co., Inc. (US) 2003-07-16 EP disclosed
US-20030055049-A1 Heteroaromatic bicyclic derivatives useful as anticancer agents PFIZER INC. 2003-03-20 US disclosed
US-6465449-B1 SUCH AS (6-(4-(6-AMINO-3-AZA-BICYCLO(3.1.0)HEX-3-YLMETHYL)-PHENYL)-QUINAZOLIN-4-YL) -(4-PHENOXY-PHENYL)-AMINE PFIZER INC. 2002-10-15 US disclosed
US-20020094989-A1 Pyrrolidine modulators of CCR5 chemokine receptor activity HALE JEFFREY J (US) 2002-07-18 US disclosed
WO-2002034716-A2 PYRROLIDINE MODULATORS OF CCR5 CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2002-05-02 WO disclosed
EP-1029853-A1 Heteroaromatic bicyclic derivatives useful as anticancer agents Pfizer Products Inc. (US) 2000-08-23 EP disclosed
EP-0413455-B1 Azabicyclo quinolone carboxylic acids PFIZER (US) 1995-06-21 EP disclosed
US-5391763-A 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids PFIZER INC. (US) 1995-02-21 US disclosed
US-5164402-A Bactericides PFIZER INC (US) 1992-11-17 US disclosed